Head-to-head · WeighScore
Nouri vs Omada Health
The verdict
Omada Health takes it — 55.6/100 to 54.8/100, but only just.
Omada Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Omada Health is a virtual care company offering behavior-change programs for weight health, diabetes and hypertension, distributed through employers and health plans. Nouri is close behind and may still be the better fit — see the factor split below.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Nouri | Omada Health |
|---|---|---|
| WeighScore | 54.8/100 | 55.6/100 |
| Grade | C | C |
| Scorecard rank | #455 | #436 |
| Semaglutide | Not disclosed | Not disclosed |
| Tirzepatide | Not disclosed | Not disclosed |
| Coverage | All 50 states | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #455 · C
Strengths
- Named clinical MSO partner (Wasef Health, PC; Michael Wasef, MD) with public contact email
- Named 503A compounding pharmacy partner (Jungle Jim's Pharmacy, Fairfield OH) with full address
- Available in all 50 states per the FAQ
- Flat per-dose pricing within each tier — no dose-escalation surcharge
- Nutrition and movement coaching included in the medication price
Where it loses points
- Compounded medications only — no FDA-approved Wegovy, Ozempic, Mounjaro, or Zepbound
- Operating entity name not disclosed in the Terms of Service
- Terms 'where we operate' language is slightly weaker than the FAQ's all-50-states claim
- Video visit required in some states, but those states aren't listed
- FDA has issued this company a warning letter; the letter is public in FDA's warning-letter database
Graded #436 · C
Strengths
- Added GLP-1 prescribing and medication management in late 2025
- Clinicians trained in obesity care, available in all 50 states
- Behavioral support wrapped before, during and after treatment
- GLP-1 Flex Care adds a cash-pay medication pathway in 2026
- Publicly traded, evidence-based virtual care platform
Where it loses points
- Core program distributed via employers and health plans, limited cash-pay
- GLP-1 prescribing is a recent addition still scaling
- GLP-1 Flex Care only rolling out to employers later in 2026
- No transparent published price for the core member program
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.